Telix Pharmaceuticals Limited
55 Flemington Road
Suite 401
North Melbourne, VIC 3051
Australia
61 3 9093 3855
https://telixpharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 415
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | Co-Founder, MD, Group CEO & Executive Director | 669.24k | 無 | 1976 |
| Mr. Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer | 571.17k | 無 | 1965 |
| Dr. Andreas Kluge M.D., Ph.D. | Chief Medical Advisor & Non-Executive Director | 43k | 無 | 1965 |
| Dr. David N. Cade M.B.A., M.D., MBBS | Group Chief Medical Officer | 無 | 無 | 1969 |
| Mr. Richard Valeix M.B.A. | Group Chief Commercial Officer | 638.49k | 無 | 1975 |
| Mr. Darren Patti | Group Chief Operating Officer | 無 | 無 | 1972 |
| Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) | Chief Scientist | 141.76k | 無 | 無 |
| Mr. Craig Ulrick | Chief Information Officer | 無 | 無 | 無 |
| Ms. Kyahn Williamson B.A. | Senior Vice President of Corporate Communications & Investor Relations | 無 | 無 | 無 |
| Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. | Senior VP of Global Governance, Risk & Compliance | 無 | 無 | 無 |
描述
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
公司管治
截至 2024年6月29日 止，Telix Pharmaceuticals Limited 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：4；董事會：2；股東權利：1；現金賠償：2。
